When Brain Metastases Meet Immunotherapy: Real-World Outcomes With First-Line Pembrolizumab in PD-L1-High Metastatic NSCLC
Background: Although immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC), the impact on brain metastases (BM) remains uncertain, as these patients have often been excluded from or underrepresented in clinical trials. The aim of this study w...